Nectid helps clinical-stage biotech companies determine what evidence
will cause a specific counterparty to fund, option, license, or advance
an asset—and then aligns business development, development strategy,
and capital around that decision.
Powered by TSCIP
Development designed backward from the transaction.
Generating the right evidence can change the asset.
What is the smallest credible evidence package that would change the next important Capital or partnering decision?
Strengths, critical uncertainties, partnerability, evidence gaps and capital requirements.
Which specific companies could act, and on which dimension of strategic fit.
Direct engagement to learn what would actually change the counterparty's decision.
The minimum credible evidence package required to cross the identified gate.
Who should finance that evidence, and through which structure.
Carrying the validated thesis into a defined strategic transaction.
Therapeutic Opportunity
IP Creation
Development Strategy
Strategic Counterparty
Transaction
Engagements routinely involve confidential company information, unpublished data and direct counterparty feedback. Materials are handled on a need-to-know basis, access is limited to the individuals working on the engagement, and counterparty conversations are conducted under agreed confidentiality terms.
That is precisely where TSCIP is designed to operate.